CETROTIDE 0.25MG

H01CC02(WHO) AU:S4(Prescription only)US:℞-onlyEU:Rx-only Acetyl-D-3-(2′-naphtyl)-alanine-D-4-chlorophenylalanine-D-3-(3′-pyridyl)- alanine-L-serine-L-tyrosine-D-citrulline-L-leucine-L-arginine-L-proline-D-alanine-amide 120287-85-6Y 16130924 1190 DB00050Y 10482082Y OON1HFZ4BA D07665Y CHEBI:59224Y ChEMBL1200490N DTXSID7040996 Interactive image CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(9‍‍‍‍‍‍​​​‍​​​​​​8)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1YKey:SBNPWPIBESPSIF-MHWMIDJBSA-NY Cetrorelix(INNTooltip International Nonproprietary Name,BANTooltip British Approved Name), orcetrorelix acetate(USANTooltip United States Adopted Name,JANTooltip Japanese Accepted Name), sold under the brand nameCetrotide, is an injectablegonadotropin-releasing hormone(GnRH)antagonist. Asyntheticdecapeptide, it is used in assisted reproduction to inhibit premature luteinizing hormone surgesThe drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action ofluteinizing hormone(LH) andfollicle-stimulating hormone(FSH). In addition, cetrorelix can be used to treat hormone-sensitive cancers of the prostateand breast (in pre-/perimenopausal women)and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning).It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; ifhuman chorionic gonadotropin(hCG) is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered. It is available as ageneric medication.